



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)	Group Art Unit: To Be Assigned
)	
BEE <i>et al.</i>)	Examiner: To Be Assigned
)	
Serial No.: 10/632,658)	Atty. Docket No. GP103-03.DV1
)	
Filed: August 1, 2003)	Confirmation No.: To Be Assigned
)	
For: DETECTION OF <i>HIV-1</i> BY)	
NUCLEIC ACID AMPLIFICATION)	

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants bring to the Examiner's attention the references listed on the enclosed form PTO/SB/08 (two copies) for consideration in connection with the examination of the above-identified application. Copies of the cited references are enclosed herewith, except for the cited US patents and published applications.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being submitted within three months of the certified filing date of the instant application, and before the mailing date of a first Office Action on the merits.

IDS



Application Serial No.: 10/632,658
Atty. Docket No. GP103-03.DV1

Applicants respectfully request that the Examiner indicate consideration of the cited references by returning a copy of the enclosed form PTO/SB/08 with the Examiner's initials or other appropriate marks.

No fee is believed due in connection with this Information Disclosure Statement. If Applicants are mistaken, please charge the amount due to Deposit Account No. 07-0835 in the name of Gen-Probe Incorporated.

Respectfully Submitted,

Date: October 31, 2003

By: Christine A. Gritzmacher
Christine A. Gritzmacher
Registration No. 40,627
Attorney for Applicants
GEN-PROBE INCORPORATED
Patent Department
10210 Genetic Center Drive
San Diego, California 92121
PH: 858-410-8927
FAX: 858-410-8928



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1999, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/632,658
Filing Date	Aug. 1, 2003
First Named Inventor	Gary G. Bee
Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	GP103-03.DV1

Sheet 1 of 6

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 5,075,211	12/24/1991	Cosand et al.	
		US- 5,185,439	02/09/1993	Arnold, Jr. et al.	
		US- 5,384,242	01/24/1995	Oakes	
		US- 5,399,491	03/21/1995	Kacian et al.	
		US- 5,427,930	06/27/1995	Birkenmeyer et al.	
		US- 5,457,840	12/05/1995	Acevedo et al.	
		US- 5,554,516	09/10/1996	Kacian et al.	
		US- 5,569,582	10/29/1996	Tavernarakis et al.	
		US- 5,582,989	12/10/1996	Caskey et al.	
		US- 5,599,662	02/04/1997	Respass	
		US- 5,602,240	02/11/1997	De Mesmaeker et al.	
		US- 5,629,158	05/13/1997	Uhlen	
		US- 5,629,413	05/13/1997	Peterson et al.	
		US- 5,658,737	08/19/1997	Nelson et al.	
		US- 5,684,147	11/04/1997	Agrawal et al.	
		US- 5,688,637	11/18/1997	Moncany et al.	
		US- 5,693,535	12/02/1997	Draper et al.	
		US- 5,700,922	12/23/1997	Cook	
		US- 5,702,365	01/06/1998	Ryder et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		DE 19850186 A1	05/25/2000	Roche Diagnost.		
		EP 0504278 B1	01/15/1997	Pharmacia		
		EP 0516540 B1	01/29/1997	CIS Bio Intl.		
		EP 1285971	02/26/2003	Tibotec Pharm.		
		WO 00/68436 A1	11/16/2000	Bosbach et al.		
		WO 93/07259 A1	04/15/1993	Sclerose-Foren.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/632,658
Filing Date	Aug. 1, 2003
First Named Inventor	Gary G. Bee
Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	GP103-03.DV1

Sheet 2 of 6

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 5,710,029	01/20/1998	Ryder et al.	
		US- 5,712,385	01/27/1998	McDonough et al.	
		US- 5,739,308	04/14/1998	Kandimalia et al.	
		US- 5,759,770	06/02/1998	Guertler et al.	
		US- 5,759,773	06/02/1998	Tyagi et al.	
		US- 5,763,171	06/09/1998	Stefano	
		US- 5,770,427	06/23/1998	Guertler et al.	
		US- 5,786,177	07/28/1998	Moncany et al.	
		US- 5,798,205	08/25/1998	Hauser et al.	
		US- 5,827,656	10/27/1998	Nelson et al.	
		US- 5,840,480	11/24/1998	Guertler et al.	
		US- 5,856,088	01/05/1999	McDonough et al.	
		US- 5,861,242	01/19/1999	Chee et al.	
		US- 5,919,701	07/06/1999	Peterson et al.	
		US- 5,962,225	10/05/1999	Ramberg	
		US- 5,962,665	10/05/1999	Kroeger et al.	
		US- 5,998,593	12/07/1999	Huff et al.	
		US- 6,001,558	12/14/1999	Backus et al.	
		US- 6,001,977	12/14/1999	Chang et al.	

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 99/07898 A1	02/18/1999	Akzo Nobel NV		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4

of 6

Compleat if Known

Application Number	10/632,658
Filing Date	Aug. 1, 2003
First Named Inventor	Gary G. Bee
Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	GP103-03.DV1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 6,458,540	10/01/2002	Ramberg	
		US- 6,492,110	12/10/2002	Hahn et al.	
		US- 6,528,626	03/04/2003	Guertler et al.	
		US- 6,531,137	03/11/2003	Guertler et al.	
		US- 6,531,587	03/11/2003	Guertler et al.	
		US- 6,534,273	03/18/2003	Weisburg et al.	
		US- 6,548,635	04/15/2003	Hauser et al.	
		US- 6,551,824	04/22/2003	Guertler et al.	
		US- 6,582,920	06/24/2003	Yang et al.	
		US- 6,623,920	09/23/2003	Bee et al.	
		US- 5,457,025	10/10/1995	Collins et al.	
		US- 5,459,243	10/17/1995	Acevedo et al.	
		US- 20020028459 A1	03/07/2002	Weisburg et al.	
		US- 20020068821 A1	06/06/2002	Gundling	
		US- 20020155428 A1	10/24/2002	Guertler et al.	
		US- 20020172939 A1	11/21/2002	Guertler et al.	
		US- 20030003442 A1	01/02/2003	Guertler et al.	
		US- 20030003443 A1	01/02/2003	Guertler et al.	
		US- 20030143535 A1	07/31/2003	Lyamichev et al.	

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	† ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/632,658
		Filing Date	Aug. 1, 2003
		First Named Inventor	Gary G. Bee
		Art Unit	To Be Assigned
		Examiner Name	To Be Assigned
Sheet 5	of 6	Attorney Docket Number GP103-03.DV1	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AGRAWAL et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus", Proc. Natl. Acad. Sci., USA 85: 7079-7083 (1988).	
		BELL et al. "Specificity of Polymerase Chain Amplification Reactions for Human Immunodeficiency Virus Type 1 DNA Sequences", AIDS Res Hum Retroviruses, 5(1): 87-95 (1989).	
		BILLYARD et al. "Detection of HIV-1 RNA from Plasma Specimens Using Transcription Mediated Amplification", Clin. Chem. 41(11): 1684 (1995) (Abstract XP-000978913).	
		BILLYARD et al. "Early Detection of HIV-1 RNA with Transcription Mediated Amplification", Transfusion, 37(9): S386 (1997) (Abstract XP000980447).	
		BUSH et al. "Detection of Human Immunodeficiency Virus Type 1 RNA in Plasma Samples...", J.Clin. Microbiol. 30(2): 281-286 (1992).	
		DE et al., "Detection of Human Immunodeficiency Virus (HIV) and Human Lymph. Virus (HTLV) Type I or II Dual Infect. by Polymerase Chain Reaction", Oncogene 4: 1533-1535 (1989)	
		DEBAAR et al. "Design and Evaluation of a Human Immunodeficiency Virus Type 1 RNA Assay...", J. Clin. Microbiol., 37: 1813-1818 (1999).	
		DEBYSER et al. "Failure to Quantify Viral Load with Two of the Three Commercial Methods...", Aids Res. Hum. Retroviruses 14(5): 453-459 (1998).	
		DELORD et al. "Analysis of HIV-1 expression in vivo with in situ hybridization and the polymerase chain reaction", Mol. & Cell. Probes 6: 215-221 (1992).	
		GARDUNO et al. "Early detection of HIV-1 RNA from sero-conversion panels using Gen-Probe's...", Clin Chem. 43(11): 2221 (1997) Abstract XP-000978914).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Applicati n Number	10/632,658
		Filing Date	Aug. 1, 2003
		First Named Inventor	Gary G. Bee
		Art Unit	To Be Assigned
		Examiner Name	To Be Assigned
Sheet 6	of 6	Attorney Docket Number	GP103-03.DV1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HEWLETT et al. "Co-amplification of multiple regions of the HIV-1 genome by the polymerase chain reaction: potential use...", Oncogene, 4(9): 1149-1151 (1989).	
		LEPARC, "Nucleic Acid Testing for Screening Donor Blood", Infect. Med., 17(5): 320-333 (2000).	
		MATTHEWS et al., "Analytical Strategies for the Use of DNA Probes", Analytical Biochem., 169: 1-25 (1988).	
		O'SHEA et al., "Problems in the Interpretation of HIV-1 Viral Load Assays Using Commercial Reagents", J.Med. Virol., 61: 187-194 (2000).	
		OU et al., "DNA Amplification for Direct Detection of HIV-1 in DNA of Peripheral Blood Mononuclear Cells", Science, 239: 295-297 (1988).	
		PIENIAZEK et al., "Identification of mixed HIV-1/HIV-2 infections in Brazil by polymerase chain reaction", AIDS, 5(11): 1293-1299 (1991).	
		VAN GEMEN et al., "The One-tube Quantitative HIV-1 RNA NASBA: Precision, Accuracy ...", PCR Methods & Applns., 4:S177-S184 (1995) Cold Spring Harbor Laboratory.	
		YANG et al., "Detection of HIV-1 RNA Subtypes with Transcription-Mediated Amplification", Abstracts of the General Meeting of the ASM, 97:538 (1997) (Abstract) XP-000980335.	
		ZIMMERMANN et al., "Rapid Nonradioactive Detectioof HIV-1 RNA from a Single-Cell Equivalent...", Biotechniques 15(5): 806, 808 (1993).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Image

Approved for use through 08/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/632,658
	Filing Date	August 1, 2003
	First Named Inventor	Gary G. Bee
	Art Unit	To Be Assigned
	Examiner Name	To Be Assigned
Total Number of Pages in This Submission	Attorney Docket Number	GP103-03.DV1

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Copies of 26 References
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Christine A. Gritzmacher Reg. No. 40,627
Signature	<i>Christine A. Gritzmacher</i>
Date	10/31/2003

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	Christine Gritzmacher
Signature	<i>Christine A. Gritzmacher</i>
Date	10/31/2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.